Print velocity effects on strain-rate sensitivity of acrylonitrile-butadiene-styrene using material extrusion additive manufacturing

The strain-rate sensitivity of the yield stress for Acrylonitrile-Butadiene-Styrene (ABS) tensile samples processed via material extrusion additive manufacturing (ME-AM) was investigated. Such specimens show molecular orientation and interstitial voids that affect the mechanical properties. Apparent densities were measured to compensate for the interstitial voids. Three different printing speeds were used to generate ME-AM tensile test samples with different molecular orientation. Printing velocities influenced molecular orientation and stretch, as determined from thermal shrinkage measurements. Likewise, infill velocity affected the strain-rate dependence of the yield stress. The ABS material manifests thermorheollogically simple behavior that can correctly be described by an Eyring flow rule. The changing activation volume, as a result of a varying print velocity, scales linearly with the molecular orientation, as captured in an estimated processing-induced pre-strain. Therefore, it is suggested that ME-AM processed ABS shows a deformation-dependent activation volume. This paper can be seen as initial work that can help to improve quantitative predictive numerical tools for ME-AM, taking into account the effects that the processing step has on the mechanical properties

Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26 : implications for genetic counselling and etiology of FSHD1

Contains fulltext : 23865___.PDF (publisher's version ) (Open Access

More insight in the genetic mechanisms underlying facioscapulohumeral muscular dystrophy

Item does not contain fulltex

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all